Kura Oncology, Inc. (KURA)

Kura Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	57.38	50.57	47.05	46.54	31.5	19.65
Research & Development	126.31	115.24	92.81	84.72	60.4	47.83
Operating Expenses	183.69	165.8	139.87	131.26	91.9	67.48
Operating Income	-183.69	-165.8	-139.87	-131.26	-91.9	-67.48
Interest Expense / Income	1.58	1.55	0.23	0.41	0.58	0.58
Other Expense / Income	-17.19	-14.72	-4.25	-1.21	-2.85	-4.92
Pretax Income	-168.09	-152.63	-135.84	-130.47	-89.63	-63.14
Net Income	-168.09	-152.63	-135.84	-130.47	-89.63	-63.14
Shares Outstanding (Basic)	84	73	67	66	53	42
Shares Outstanding (Diluted)	84	73	67	66	53	42
Shares Change	22.66%	9.31%	0.96%	25.01%	26.54%	19.20%
EPS (Basic)	-2.17	-2.08	-2.03	-1.97	-1.69	-1.51
EPS (Diluted)	-2.17	-2.08	-2.03	-1.97	-1.69	-1.51
Free Cash Flow	-138.01	-124.99	-110.69	-105.7	-72	-54.76
Free Cash Flow Per Share	-1.65	-1.71	-1.65	-1.59	-1.36	-1.30
EBITDA	-165.63	-150.23	-134.85	-129.49	-88.85	-62.56
Depreciation & Amortization	0.88	0.85	0.76	0.56	0.19	0
EBIT	-166.5	-151.08	-135.61	-130.05	-89.05	-62.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).